[Intravitreal bevacizumab in the treatment of idiopathic juxtafoveal telangiectasis type I].

Abstract

CLINICAL CASE:

We report a case of a 42 year-old male with a macular edema due to idiopathic juxtafoveal retinal telangiectasis type i, treated with 3 sequential injections of intravitreal bevacizumab (1.25 mg in 0.05 ml). Anatomical improvements were observed after one year of follow up.

DISCUSSION:

There is currently no general consensus regarding the treatment of unilateral idiopathic juxtafoveal telangiectasis. The therapeutic options are, grid laser photocoagulation, intravitreal triamcinolone, verteporfin photodynamic therapy, or anti-VEGF. Visual acuity and anatomical improvements were observed in this case after intravitreal bevacizumab. Thus, intravitreal bevacizumab seems to be effective to treat macular edema in idiopathic juxtafoveal telangiectasis type i.

• Authors: A García-Ben, F Gómez-Ulla, M J Rodriguez-Cid
• Journal: Archivos de la Sociedad Espanola de Oftalmologia (Arch Soc Esp Oftalmol) Vol. 89 Issue 7 Pg. 269-71 (Jul 2014) ISSN: 1989-7286 [Electronic] Spain
• Vernacular Title: Bevacizumab intravítreo como tratamiento de las telangiectasias yuxtafoveales idiopáticas tipo i.
• PMID: 24269459 (Publication Type: Case Reports, English Abstract, Journal Article)
• Copyright: Copyright © 2011 Sociedad Española de Oftalmología. Published by Elsevier Espana. All rights reserved.

Chemical References

• Angiogenesis Inhibitors
• Bevacizumab

Topics

• Adult
• Angiogenesis Inhibitors (administration & dosage)
• Bevacizumab (administration & dosage)
• Humans
• Intravitreal Injections
• Male
• Retinal Telangiectasis (drug therapy)